Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Legal Officer
November 01 2021 - 4:02PM
Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology
company developing advanced small molecule and immunotherapy
treatments to transform care for hormone-driven breast and
gynecological cancers, today announced the appointment of Jennifer
Minai-Azary as Chief Financial Officer and the prior appointment,
in April 2021, of Alex Levit as Chief Legal Officer.
“It is an exciting time for the company following our recent
debut on Nasdaq and I’d like to thank Alex for all of his
contributions to help make this happen. I’m also pleased to welcome
Jennifer Minai-Azary to Context’s leadership team,” said Martin
Lehr, Chief Executive Officer of Context. “Jennifer’s and Alex’s
deep biopharma financial and legal expertise, respectively, and
their proven leadership skills will be instrumental to Context as
we navigate this new chapter for the company and work to deliver on
our near- and long-term corporate and clinical milestones.”
Ms. Minai-Azary brings more than 20 years of finance and
accounting experience to Context. Prior to joining Context, Ms.
Minai-Azary served in roles of increasing responsibility at
Millendo Therapeutics, culminating in chief financial officer,
where she led financial operations, including guiding the company’s
merger with Tempest Therapeutics, a clinical-stage oncology
company. Earlier in her career, Ms. Minai-Azary was director of
technical accounting at Parexel and began her career in Ernst &
Young’s audit practice. Ms. Minai-Azary holds a Master of
Accounting and a Bachelor of Business Administration from the
University of Michigan and is a certified public accountant.
“I’m excited to join Context at this important juncture in the
company’s growth and I look forward to leading the company’s
finance organization,” said Ms. Minai-Azary. “I am eager to help
deliver on the company’s ongoing commitment to provide patients
with more therapeutic options and to drive long-term value for our
shareholders.”
Mr. Levit is a seasoned legal advisor with nearly two decades of
industry experience advising public and private companies. Prior to
joining Context, Mr. Levit served as vice president, deputy general
counsel and assistant corporate secretary of OptiNose, a publicly
held specialty pharmaceutical company. Previously, Mr. Levit was
associate general counsel of Teva Pharmaceuticals, a global
pharmaceutical company. During his tenures at OptiNose and Teva,
Mr. Levit negotiated various in-bound and out-bound licenses,
collaborations, and mergers and acquisitions, as well as clinical
trial agreements and supply agreements. Earlier in his career,
Mr. Levit was an attorney at Reed Smith LLP. Mr. Levit currently
sits on the Board of Directors of Strados Labs, a medical device
company. Mr. Levit holds a J.D. from Temple University Beasley
School of Law and a Bachelor of Arts in Labor & Industrial
Relations from Pennsylvania State University, where he graduated
from the Schreyer Honors College.
“I’m inspired by Context’s important mission to address the
devastating unmet need in hormone-driven women’s cancers,” said Mr.
Levit. “I look forward to collaborating with the Context leadership
team and Board to contribute to Context’s growth and future
success.”
About Context TherapeuticsContext Therapeutics
Inc. (Nasdaq: CNTX) is a women’s oncology company developing
advanced small molecule and immunotherapy treatments to transform
care for hormone-driven breast and gynecological cancers. The
Company’s robust clinical program for lead candidate onapristone
extended release (ONA-XR) comprises three Phase 2 clinical trials
and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian
and endometrial cancer, as well as two Phase 0 biomarker
pharmacodynamic trials in breast cancer. ONA-XR is a novel small
molecule under development as a complete antagonist of the
progesterone receptor, a key unchecked mechanism in hormone-driven
women’s cancers. The Company is headquartered in Philadelphia, PA.
For more information, visit www.contexttherapeutics.com.
Forward-looking StatementsThis press release
contains “forward-looking statements” that involve substantial
risks and uncertainties for purposes of the safe harbor provided by
the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, included in
this press release regarding strategy, future operations,
prospects, plans and objectives of management, including words such
as "may," "will," "expect," "anticipate," "plan," "intend," and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
forward-looking statements. These include, without limitation,
statements regarding (i) the results of our clinical trials, (ii)
the potential benefits of the product candidates, (iii) the
likelihood data will support future development, and (iv) the
likelihood of obtaining regulatory approval of our product
candidates. Forward-looking statements in this release involve
substantial risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by the
forward-looking statements, and we, therefore cannot assure you
that our plans, intentions, expectations or strategies will be
attained or achieved. Other factors that may cause actual results
to differ from those expressed or implied in the forward-looking
statements in this press release are discussed in our filings with
the U.S. Securities and Exchange Commission, including the
section titled “Risk Factors” contained therein. Except as
otherwise required by law, we disclaim any intention or obligation
to update or revise any forward-looking statements, which speak
only as of the date they were made, whether as a result of new
information, future events or circumstances or otherwise.
Media Contact:Heather Anderson6
Degrees919-827-5539handerson@6degreespr.com
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From May 2024 to Jun 2024
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Jun 2023 to Jun 2024